Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
28 mai 2024 07h35 HE
|
Numab Therapeutics AG
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
20 mai 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
16 mai 2024 06h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
15 mai 2024 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
13 mai 2024 16h01 HE
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
09 mai 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08 mai 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
SkinCure Oncology’s GentleCure™ Experience to be Featured in National Public Health PSA Series
08 mai 2024 09h00 HE
|
SkinCure Oncology LLC
GentleCure will be recognized as an innovative healthcare technology in an upcoming public service announcement (PSA) about nonmelanoma skin cancer.
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
07 mai 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
06 mai 2024 08h00 HE
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.